Funded Biotechnology Startups in Redwood City
Redwood City has generated a concentrated run of biotechnology financings over the past five years, with the 23 companies shown ranging from a $100K grant…
Redwood City has generated a concentrated run of biotechnology financings over the past five years, with the 23 companies shown ranging from a $100K grant (Mango Materials, March 2022) to Revolution Medicines' $750M raise in December 2024 — the largest disclosed round in this set. Activity has accelerated in the most recent 24 months: seven rounds closed in 2024 and five more had already closed by mid-August 2025, including Kriya Therapeutics' $313M Series C and Soleno Therapeutics' $200M raise in July 2025.
Therapeutics companies account for the majority of entries, with oncology, rare disease, and gene therapy each represented by multiple names. A notable share of rounds carry no labeled stage — common across this list's late-stage and publicly traded companies — while genuine early-stage activity is limited to a handful of Seed and Series A deals, including REMspace's $1M Seed in July 2024 and Eigen Therapeutics' $7M Seed in December 2022. Round sizes cluster heavily at the high end: seven disclosed rounds exceed $100M.
Most recent rounds
23 shownRelated listings
Frequently asked
What are the largest rounds among Redwood City biotech companies in this dataset?
Revolution Medicines leads at $750M (December 2024), followed by Kriya Therapeutics at $313M Series C (August 2025) and Soleno Therapeutics at $200M (July 2025). Maze Therapeutics ($190M, January 2022) and Nuvig Therapeutics ($161M Series B, December 2024) round out the top five by disclosed amount.
Which companies closed rounds most recently?
The five most recent closes are Kriya Therapeutics (Series C, $313M, August 15 2025), Heron Therapeutics ($145M, August 8 2025), Soleno Therapeutics ($200M, July 10 2025), Biomea Fusion ($40M, June 17 2025), and Ashvattha Therapeutics (Series B, $50M, January 13 2025).
Why do so many rounds in this list show 'Series Unknown' instead of a labeled stage?
Several companies here — including Revolution Medicines, Heron Therapeutics, Soleno Therapeutics, and Coherus Biosciences — are publicly traded or late-stage, making traditional venture stage labels inapplicable. 'Series Unknown' in this context typically reflects registered direct offerings, at-the-market programs, or structured raises that don't map to a conventional Series A/B/C progression.
How active has Redwood City biotech fundraising been in 2024 and 2025?
Seven of the 23 rows closed in 2024, led by Revolution Medicines ($750M in December) and Karius ($100M Series C in May). Five closed in 2025 through mid-August — collectively accounting for over $748M in disclosed capital across Kriya, Heron, Soleno, Biomea Fusion, and Ashvattha.
Are there any early-stage biotechs in Redwood City represented here?
Two Seed rounds appear: REMspace ($1M, July 2024) and Eigen Therapeutics ($7M, December 2022). AmMax closed an undisclosed Series A in August 2022. These three represent the early-stage tail of a dataset otherwise dominated by growth-phase and late-stage raises.
What therapeutic focus areas are most represented among these companies?
Therapeutics development is the dominant category, covering gene therapy (Kriya Therapeutics), RAS-targeted oncology (Revolution Medicines), rare disease (Soleno Therapeutics, Maze Therapeutics), immuno-oncology (Bolt Biotherapeutics), and hematology (Jasper Therapeutics). Diagnostics (Karius), enzyme engineering (Codexis), and cognitive health monitoring (Neurotrack) also appear, though each as a single entry.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.